OctoPlus announces equity raising with net proceeds of ? 3 million
(Thomson Reuters ONE) -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO
OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), announces today
that it has successfully completed an equity raising with ? 3 million net
proceeds through a private placement of 7.9 million shares at an offer price of
? 0.40 per share with OGBB A. van Herk B.V. (the "Private Placement"). OctoPlus
intends to use the proceeds of the Private Placement for working capital
purposes and to invest in projects with financial upside potential.
The shares will be issued in two tranches. The first tranche of 3 million shares
(the "First Tranche Shares") will be issued today, while the second tranche of
4.9 million shares (the "Second Tranche Shares") will be issued after and
subject to the Executive Board of OctoPlus having been delegated the authority
to issue additional shares, by the Annual General Meeting of Shareholders which
is scheduled on 13 June 2012. The agenda and the explanatory notes of this
meeting will be published shortly on the website of OctoPlus.
Jan Egberts, CEO of OctoPlus, says: "We are very pleased with the confidence
that Van Herk has shown in OctoPlus and our management team. We are looking
forward to work together to further strengthen and expand on our key strategic
initiatives."
As a result of the Private Placement, the total number of shares outstanding
will increase to 47,778,974 shares following the issuance of the First Tranche
Shares and to 52,673,974 shares following the issuance of the Second Tranche
Shares. The First Tranche Shares are expected to be admitted to listing and
trading on Euronext Amsterdam by NYSE Euronext ("Euronext Amsterdam") on or
about 27 April 2012.
Contact
For further information about OctoPlus and the Private Placement, please contact
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071 or
send an e-mail to Investor Relations at IR(at)octoplus.nl.
About OctoPlus
OctoPlus is a specialty pharmaceutical company focused on the development and
manufacture of improved injectable pharmaceuticals based on our proprietary drug
delivery technologies that exhibit fewer side effects, improved patient
convenience and a better efficacy/safety balance than existing therapies.
OctoPlus also focuses on the development of long-acting, controlled release
versions of known protein therapeutics, peptides and small molecules, including
specialty generics.
The clinically most advanced product incorporating our technology is Locteron®,
a controlled release formulation of interferon alpha for the treatment of
chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October
2008. Locteron is being manufactured for Biolex by OctoPlus and has recently
completed Phase IIb clinical studies with superior clinical data versus current
treatment.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate active
pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For more
information about OctoPlus, please visit our website www.octoplus.nl.
This announcement is not an offer to sell or a solicitation of any offer to buy
the securities of OctoPlus (the "Securities") in the United States or in any
other jurisdiction.
The shares have not been and will not be registered under the U.S. Securities
Act of 1933, as amended (the "Securities Act"), and may not be offered or sold
in the United States or to or for the account or benefit of, U.S. persons (as
such term is defined in Regulation S under the Securities Act) unless registered
under the Securities Act or an exemption from such registration is available. No
public offering of Securities of OctoPlus is being made in the United States.
This announcement does not constitute a prospectus.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of the Company and the industry in
which it operates. These statements are based on OctoPlus N.V.'s current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
Click here for the press release in PDF format:
http://hugin.info/137076/R/1605981/508796.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE
[HUG#1605981]
Unternehmensinformation / Kurzprofil:
Datum: 25.04.2012 - 17:45 Uhr
Sprache: Deutsch
News-ID 139259
Anzahl Zeichen: 6153
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 264 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OctoPlus announces equity raising with net proceeds of ? 3 million"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
